Cytomedix falls 25% as it turns to three-pronged financing plan
This article was originally published in Scrip
Executive Summary
Cytomedix stock lost 25% of its value on 20 February when the Gaithersburg, Maryland-based company specializing in autologous regenerative therapies announced three different financing vehicles designed to generate up to $27.5 million for its "2013 operational business plan."